Skip to content

Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain

Treatment of Overactive Bladder, Lower Urinary Tract Symptoms and Pelvic Pain With Medium Frequency Electrotherapy (Interferential Currents)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03520166
Enrollment
100
Registered
2018-05-09
Start date
2014-01-10
Completion date
2017-06-30
Last updated
2018-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Urinary Tract Symptoms, Pelvic Pain, Urinary Bladder, Overactive

Keywords

urgency, frequency, overactive bladder, LUTS, pelvic pain, electrostimulation

Brief summary

The aim of this study is to assess the effectiveness of medium frequency electrotherapy (interferential currents) treatment for overactive bladder (OAB), lower urinary tract symptoms (LUTS) and pelvic pain

Detailed description

This study consists of 100 women, complaining of increased bladder sensation and urgency with or without incontinence as principal symptomatology and who had not received previous pharmacological treatment. Group-A was used as a control group (n = 50). Group-B patients received 18 sessions of medium frequency electrotherapy during 9 weeks, 2 weekly sessions

Interventions

OTHERMedium frequency electrotherapy (interferential currents)

Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.

OTHERNo treatment

No treatment

Sponsors

Fisioterapia Pélvica Avanzada Madrid, SRL
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Type inclusion was consecutively type

Intervention model description

Quasi-experimental, longitudinal, pre-/post-. Level of evidence II/III.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Increased bladder sensation Urgency Overactive bladder Lower urinary tract symptoms Pelvic pain

Exclusion criteria

Neurogenic bladder Acute urinary infection Pelvic floor surgery Congenital urological malformations Age less than 18 years Bladder organic pathology Pelvic radiotherapy

Design outcomes

Primary

MeasureTime frameDescription
urgency24 hourswith or without urge incontinence, usually with frequency and nocturia, can be described as the overactive bladder syndrome, urge syndrome or urgency-frequency syndrome. Measured with 24 hour voiding diary.

Secondary

MeasureTime frameDescription
increased daytime frequency24 hoursis the complaint by the patient who considers that he/she voids too often by day. Measured with 24 hour voiding diary.
nocturia24 hoursis the complaint that the individual has to wake at night one or more times to void. Measured with 24 hour voiding diary.
increased bladder sensation24 hoursthe individual feels an early and persistent desire to void. Measured with 24 hour voiding diary.
urge urinary incontinence24 hoursis the complaint of involuntary leakage accompanied by or immediately preceded by urgency. Measured with 24 hour voiding diary.
nocturnal enuresis24 hoursis the complaint of loss of urine occurring during sleep. Measured with 24 hour voiding diary.
incontinence24 hoursis the complaint of any involuntary leakage of urine. Measured with 24 hour voiding diary.
pelvic pain24 hoursis less well defined than, for example, bladder, urethral or perineal pain and is less clearly related to the micturition cycle or to bowel function and is not localised to any single pelvic organ. Measured with pain visual analogic pain scale single-item scale.
feeling of incomplete emptying24 hoursis a self-explanatory term for a feeling experienced by the individual after passing urine. Measured with 24 hour voiding diary.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026